Results 151 to 160 of about 14,917 (240)

Prognostic Impact of the AML60+ Score for Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Retrospective Multicentric Analysis. [PDF]

Cancers (Basel)
Petermichl V, Fuchs S, Weber M, Gobat K, Micheloud C, Graf L, Gerth Y, Goede JS, Lehmann T, Driessen C, Mey UJM, Cathomas R, Cogliatti S, Silzle T.   +13 more
europepmc   +1 more source

News on hypomethylating agents: Chasing the FOX [PDF]

Cell Cycle, 2011
openaire   +1 more source

Efficacy assessment following shortened venetoclax exposure in AML patients treated with venetoclax plus hypomethylating agents: a real-world, multicentric study. [PDF]

Blood Cancer J
Wurm S, Moritz JM, Petzer V, Wolf D, Gleixner KV, Sperr WR, Groiss C, Machherndl-Spandl S, Eisenwort G, Koller E, Schoeche J, Petrasch C, Singer J, Mayer DM, Pregartner G, Heine A, Wölfler A, Sill H, Reinisch A, Zebisch A.   +19 more
europepmc   +1 more source

Comparative efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia treatment: a meta-analysis of clinical trials and Real-World outcomes. [PDF]

Ann Hematol
Sanz-Solas A, Saiz-Rodríguez M, Simal SC, Rodríguez-Veiga R, Solana-Altabella A, Montesinos P, Labrador J.   +6 more
europepmc   +1 more source

Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for acute myeloid leukemia cell self-renewal. [PDF]

Leukemia
Bond DR, Burnard SM, Uddipto K, Hunt KV, Harvey BM, Steffens Reinhardt L, Lawlor-O'Neill C, Roper EA, Humphries S, Murray HC, Mannan A, Dun MD, de Bock CE, Bowden NA, Enjeti AK, Verrills NM, Riveros C, Lê Cao KA, Lee HJ.   +18 more
europepmc   +1 more source

Ivosidenib or venetoclax combined with hypomethylating agents in <i>IDH1</i>-mutated acute myeloid leukemia: a real-world study. [PDF]

Blood Neoplasia
Lachowiez CA, Smith BD, Ambinder AJ, Binder G, Angiolillo A, Potluri R, Papademetriou E, LeBlanc TW.   +7 more
europepmc   +1 more source

The Effectiveness of Hypomethylating Agents in Elderly Patients With Acute Myeloid Leukemia: Insights From a Single-Center Experience. [PDF]

Cureus
Negotei C, Mitu I, Stanca O, Angelescu S, Lapadat ME, Barta C, Berbec NM, Colita A.   +7 more
europepmc   +1 more source

Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1-Mutated Acute Myeloid Leukemia. [PDF]

Cancer Med
Cai Y, Rui J, Ding Z, Xie J, Jin Z, Xiao J, Xu Y.   +6 more
europepmc   +1 more source

Venetoclax and hypomethylating agents versus tagraxofusp in older patients with blastic plasmacytoid dendritic cell neoplasm. [PDF]

Ann Hematol
Lee BJ.
europepmc   +1 more source

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms [PDF]

, 2018
Abboud, Camille N.
core   +1 more source